Cambridge, UK, 18 September 2017 – Microbiotica, a leading player in microbiome-based therapeutics, announces that it was chosen as the winner of the ‘Life Science Spin-out of the Year’ at the recent Biotech and Money 2017 Awards.
The award recognises both Microbiotica’s potential in the microbiome sector and its achievements to date as the newest spin-out company from the world-renowned Wellcome Trust Sanger Institute, Cambridge, including its £8m equity financing in 2016 from Cambridge Innovation Capital and IP Group. The Company is at the forefront of understanding how the microbiome can be used to develop new therapeutics for a range of diseases and to stratify patients according to their microbiata.
Votes for each category were determined 50% by advanced online voting and 50% by a live vote on the night of the Awards dinner, which was held in London on 14 September.
Dr Mike Romanos, CEO of Microbiotica, said: “It is rewarding for our team to achieve this recognition in the first year. Being selected for this award by our peers is a great endorsement of the strength of Microbiotica’s science and the progress made by its talented team.”